Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Home
  • Home
Article
  • Cited by 11

  • Access

Assessment of humoral and cell-mediated immunity against Bordetella pertussis in adolescent, adult, and senior subjects in Italy

  • G. GABUTTI (a1), M. BERGAMINI (a1), P. BONANNI (a2), M. GUIDO (a3), D. FENOGLIO (a4), A. GIAMMANCO (a5), L. SINDONI (a6), C. ZOTTI (a7), V. BODDI (a2), F. BAMFI (a8), R. SEVERINI (a1), A. BECHINI (a2), S. BOCCALINI (a2) and P. CROVARI (a9)...

Summary

Humoral and cell-mediated immunity (CMI) against B. pertussis was assessed in a sample of adolescent, adult and senior subjects distributed in five different geographical areas in Italy. Most (99·1%) subjects had IgG anti-pertussis toxin (PT) antibodies exceeding the minimum detection level [⩾2 ELISA units (EU)/ml]. There were no significant differences between the genders; 6·2% samples recorded titres ⩾100 EU/ml. CMI was positive [stimulation index (SI) ⩾5] against PT in 39·0% of all samples. This study suggests that B. pertussis continues to circulate in age groups that have been previously considered to be uninvolved in the circulation of this pathogen and that adolescent and adult pertussis boosters may be of value in these populations. Nevertheless, over the last 10 years, large increases in vaccination coverage rates have contributed to reduce the spread of the aetiological agent, especially in the immunized population.

    •

      • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Assessment of humoral and cell-mediated immunity against Bordetella pertussis in adolescent, adult, and senior subjects in Italy
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Assessment of humoral and cell-mediated immunity against Bordetella pertussis in adolescent, adult, and senior subjects in Italy
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Assessment of humoral and cell-mediated immunity against Bordetella pertussis in adolescent, adult, and senior subjects in Italy
      Available formats
      ×

Copyright

COPYRIGHT: © 2008 Cambridge University Press

Corresponding author

*Author for correspondence: Professor G. Gabutti, Department of Clinical and Experimental Medicine, Section of Hygiene and Occupational Health, University of Ferrara, Via Fossato di Mortara, 64b – 44100 Ferrara, Italy. (Email: giovanni.gabutti@unife.it)

References

Hide All
1. Mortimer, EA Jr.. Pertussis. In: Evans, AS, Brachman, PS. Bacterial Infections of Humans, 3rd edn.New York and London: Plenum Medical Book Co., 1998, pp. 529–543.
2. Hewlett, EL, Halperin, SA. Serological correlates of immunity to Bordetella pertussis. Vaccine 1998; 16: 1899–1900.
3. Locht, C, Antoine, R, Jacob-Dubuisson, F. Bordetella pertussis, molecular pathogenesis under multiple aspects. Current Opinion in Microbiology 2001; 4: 82–89.
4. Tamura, M, et al. Subunit structure of islet-activating protein, pertussis toxin, in conformity with the A-B model. Biochemistry 1982; 21: 5516–5522.
5. Ladant, D, Ullmann, A. Bordetella pertussis adenylate cyclase: a toxin with multiple talents. Trends in Microbiology 1999; 7: 172–176.
6. Robbins, JB, Pittman, M. Bordetella. In: Davis, BD, Dulbecco, R, Eisen, HN, Ginsberg, HS eds. Microbiologia. Quarta ed. Zanichelli, 1998, pp. 638–641.
7. Cookson, BT, et al. Biological activities and chemical composition of purified tracheal cytotoxin of Bordetella pertussis. Infection and Immunity 1989; 57: 2223–2229.
8. Mills, KHG. Immunity to Bordetella pertussis. Microbes and Infection 2001; 3: 655–677.
9. Campins-Martì, M, et al. Recommendations are needed for adolescent and adult pertussis immunisation: rationale and strategies for consideration. Vaccine 2001; 20: 641–646.
10. Wirsing von Konig, CH, Halperin, S, Riffelmann, M, Guiso, N. Pertussis of adults and infants. Lancet Infectious Diseases 2002; 2: 744–750.
11. Nelson, JD. The changing epidemiology of pertussis in young infants. The role of adults as reservoirs of infection. American Journal of Diseases of Children 1978; 132: 371–373.
12. Mink, CA, Sirota, NM, Nugent, S. Outbreak of pertussis in a fully immunized adolescent and adult population. Archives of Pediatrics & Adolescent Medicine 1994; 148: 153–157.
13. Wirsing von Konig, CH, et al. Pertussis in adults: frequency of transmission after household exposure. Lancet 1995; 346: 1326–1329. [Erratum in Lancet 1995; 346: 1502].
14. Senzilet, LD, et al. Sentinel Health Unit Surveillance System Pertussis Working Group. Pertussis is a frequent cause of prolonged cough illness in adults and adolescents. Clinical Infectious Diseases 2001; 32: 1691–1697.
15. Pastore Celentano, L, et al. , on behalf of the EUVAC-NET Group. Resurgence of pertussis in Europe. Pediatric Infectious Disease Journal 2005; 24: 761–765.
16. Edelman, K, et al. Immunity to pertussis 5 years after booster immunization during adolescence. Clinical Infectious Diseases 2007; 44: 1271–1277.
17. Preston, A. Bordetella pertussis: the intersection of genomics and pathobiology. Canadian Medical Association Journal 2005; 173: 55–62.
18. Storsaeter, J, et al. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 1998; 16: 1907–1916.
19. Cherry, JD, et al. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 1998; 16: 1901–1906.
20. Olin, P, et al. How to make sense of pertussis immunogenicity data. Clinical Infectious Diseases 2001; 33: S288–S291.
21. Rota, MC, et al. Prevalence of markers of exposure to Bordetella pertussis among Italian young adults. Clinical Infectious Diseases 1998; 26: 297–302.
22. Tran Minh, NN, et al. Cell-mediated immune responses to antigens of Bordetella pertussis and protection against pertussis in school children. Pediatric Infectious Disease Journal 1999; 18: 366–370.
23. Mattoo, S, Cherry, JD. Molecular pathogenesis, epidemiology and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clinical Microbiology Reviews 2005; 18: 326–382.
24. Giammanco, A, et al. European Seroepidemiology Network: standardisation of the assay results for pertussis. Vaccine 2003; 22: 112–120.
25. Pebody, RG, et al. The seroepidemiology of Bordetella pertussis infection in Western Europe. Epidemiology and Infection 2005; 133: 159–171.
26. Zuercher, AW, et al. Cellular immunity in healthy volunteers treated with an octavalent conjugate Pseudomonas aeruginosa vaccine. Clinical and Experimental Immunology 2005; 143: 132–138.
27. Disis, ML, et al. Maximizing the retention of antigen specific lymphocyte function after cryopreservation. Journal of Immunological Methods 2006; 308: 13–18.
28. Binkin, NJ, et al. Epidemiology of pertussis in a developed country with low vaccination coverage: the Italian experience. Pediatric Infectious Disease Journal 1992; 11: 653–661.
29. Ciofi degli Atti, ML, et al. Do changes in policy affect vaccine coverage levels? Results of a national study to evaluate childhood vaccination coverage and reasons for missed vaccination in Italy. Vaccine 2004; 22: 4351–4357.
30. Rota, MC, et al. How increased pertussis vaccination coverage is changing the epidemiology of pertussis in Italy. Vaccine 2005; 23: 5299–5305.
31. Purdy, KW, et al. Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost-benefit analysis. Clinical Infectious Diseases 2004; 39: 20–28.
32. Cherry, JD. The epidemiology of pertussis: a comparison of the epidemiology of the disease pertussis with the epidemiology of Bordetella pertussis infection. Pediatrics 2005; 115: 1422–1427.
33. Le, T, et al. Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT study. Journal of Infectious Diseases 2004; 190: 535–544.
34. Giammanco, A, et al. Seroepidemiology of pertussis in Italy. Reviews of Infectious Diseases 1991; 13: 1216–1220.
35. De Melker, H, et al. Specificity and sensitivity of high levels of immunoglobulin G antibodies against pertussis toxin in a single serum sample for diagnosis of infection with Bordetella pertussis. Journal of Clinical Microbiology 2000; 38: 800–806.
36. Polyzou, A, et al. Seroepidemiology of Bordetella pertussis immune responses in a healthy population in Northern Greece. Journal of Clinical Laboratory Analysis 2004; 18: 211–214.
37. Nardone, A, et al. Sero-epidemiology of Bordetella pertussis in England and Wales. Vaccine 2004; 22: 1314–1319.
38. Mills, KHG, et al. A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis. Infection and Immunity 1998; 66: 594–602.
39. Leef, M, et al. Protective immunity to Bordetella pertussis requires both B cells and CD4+ T cells for key functions other than specific antibody production. Journal of Experimental Medicine 2000; 191: 1841–1852.
40. Edelman, KJ, et al. Pertussis-specific cell-mediated and humoral immunity in adolescents 3 years after booster immunization with acellular pertussis vaccine. Clinical Infectious Diseases 2004; 29: 179–185.
41. Forsyth, KD, et al. New pertussis vaccination strategies beyond infancy: recommendations by the Global Pertussis Initiative. Clinical Infectious Diseases 2004; 39: 1802–1809.
42. American Academy of Pediatrics. Committee on Infectious Diseases. Prevention of pertussis among adolescent: recommendations for use of Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine. Pediatrics. Published online 28 December 2005. doi: 10.1542/peds.2005-3038.
43. American Academy of Pediatrics. Committee on Infectious Diseases. Recommended childhood and adolescent immunization schedule – United States, 2006. Pediatrics 2006; 117: 239–240.
44. Bamberger, ES, et al. What is new in pertussis? European Journal of Pediatrics. Published online: 1 August 2007. doi: 10.1007/S00431-007-0548-2.
45. State Regional Conference. Agreement between the central Government, Regions and Autonomous Provinces of Trento and Bolzano regarding the New National Vaccine Plan 2005–2007. Determination 3 March 2005 in conformity with the fourth paragraph of Decree no. 281, 28 August 1997. Official Bulletin (Gazzetta Ufficiale), no. 86, 14 April 2005, Ordinary Supplement no. 63.
  • Cited by 11

  • Access

Assessment of humoral and cell-mediated immunity against Bordetella pertussis in adolescent, adult, and senior subjects in Italy

  • G. GABUTTI (a1), M. BERGAMINI (a1), P. BONANNI (a2), M. GUIDO (a3), D. FENOGLIO (a4), A. GIAMMANCO (a5), L. SINDONI (a6), C. ZOTTI (a7), V. BODDI (a2), F. BAMFI (a8), R. SEVERINI (a1), A. BECHINI (a2), S. BOCCALINI (a2) and P. CROVARI (a9)...

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed